Iris Energy Limited vs Novartis AG — how do they compare? Iris Energy Limited trades at $36.59 (market cap $14.07B), while Novartis AG trades at $143.11 (market cap $268.57B). The key difference: Novartis AG is far larger — about 19.1× Iris Energy Limited's market cap, and Novartis AG pays a 3.31% dividend while Iris Energy Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Iris Energy Limited for 28 Days and Novartis AG for 82 Days on average.
| IREN | NVS | |
|---|---|---|
Market Cap | $14.07B | $268.57B |
Volume | 54,492,460 | 1,532,573 |
Sector | Technology | Health |
52-Week High | $76.41 | $168.62 |
52-Week Low | $29.31 | $121.80 |
Typical Hold Time | 28 Days | 82 Days |
Enterprise Value | $16.02B | $309.89B |
Dividend Yield | — | 3.31% |
Signals from Pluang's Aura AI — not financial advice
IREN trades at $38.69, down 6.27% today, amid a bearish technical trend and recent earnings misses. The company is aggressively pivoting from Bitcoin mining to AI infrastructure, securing multi-billion dollar contracts, but faces ballooning losses with a net income margin of -99.38% in 2026. Analyst consensus remains strongly bullish with a $81 price target, highlighting long-term revenue potential from AI demand, yet near-term execution and profitability challenges weigh on investor sentiment.
Outlook hinges on successful execution of AI expansion and cost management; opportunities include massive contracted revenue growth, but risks involve high capital burn, intense competition, and persistent negative earnings. The stock offers significant upside if targets are met, but volatility is expected amid transformative shifts.
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Iris Energy is a next-generation data center company that powers Bitcoin mining and AI workloads using 100% renewable energy. It focuses on building sustainable infrastructure for the global digital economy.
Read more on IREN →Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →